SMT201500123B - Dosaggio unitario di apadenoson - Google Patents

Dosaggio unitario di apadenoson

Info

Publication number
SMT201500123B
SMT201500123B SM201500123T SM201500123T SMT201500123B SM T201500123 B SMT201500123 B SM T201500123B SM 201500123 T SM201500123 T SM 201500123T SM 201500123 T SM201500123 T SM 201500123T SM T201500123 B SMT201500123 B SM T201500123B
Authority
SM
San Marino
Prior art keywords
apadenoson
unit dosage
dosage
unit
Prior art date
Application number
SM201500123T
Other languages
English (en)
Italian (it)
Inventor
Robert Hendel
William B Stilley
Shannon P Williams
Original Assignee
Univ Virginia Patent Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Found filed Critical Univ Virginia Patent Found
Publication of SMT201500123B publication Critical patent/SMT201500123B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SM201500123T 2008-07-03 2015-05-22 Dosaggio unitario di apadenoson SMT201500123B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7816908P 2008-07-03 2008-07-03
US15593709P 2009-02-27 2009-02-27
PCT/US2009/003939 WO2010002473A1 (en) 2008-07-03 2009-07-02 Unit dosage of apadenoson

Publications (1)

Publication Number Publication Date
SMT201500123B true SMT201500123B (it) 2015-09-07

Family

ID=41152021

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500123T SMT201500123B (it) 2008-07-03 2015-05-22 Dosaggio unitario di apadenoson

Country Status (24)

Country Link
US (6) US20100003193A1 (ko)
EP (1) EP2306971B1 (ko)
JP (2) JP2011526894A (ko)
KR (2) KR20110028531A (ko)
CN (1) CN102119023B (ko)
AU (1) AU2009266317B2 (ko)
BR (1) BRPI0913939A2 (ko)
CA (1) CA2729819C (ko)
CY (1) CY1116283T1 (ko)
DK (1) DK2306971T3 (ko)
EA (1) EA022348B1 (ko)
ES (1) ES2537069T3 (ko)
HK (1) HK1156250A1 (ko)
HR (1) HRP20150454T1 (ko)
IL (2) IL210428A (ko)
MX (1) MX2011000193A (ko)
MY (1) MY161655A (ko)
NZ (1) NZ590489A (ko)
PL (1) PL2306971T3 (ko)
PT (1) PT2306971E (ko)
SI (1) SI2306971T1 (ko)
SM (1) SMT201500123B (ko)
WO (1) WO2010002473A1 (ko)
ZA (1) ZA201100163B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2306971E (pt) 2008-07-03 2015-06-18 Univ Virginia Patent Found Dosagem unitária de apadenoson
WO2013114204A1 (en) 2012-02-03 2013-08-08 Adenobio N.V. A method of using adenosine and dipyridamole for pharmacologic stress testing, with specific compositions, unit dosage forms and kits
CN109020881B (zh) * 2018-06-28 2020-04-28 新发药业有限公司 一种阿帕替尼的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
DE69120840T2 (de) * 1990-02-21 1996-11-21 United Kingdom Government Supraleiter auf Thalliumbasis substituiert durch seltene Erden
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
DK1150991T3 (da) 1999-02-01 2004-06-07 Univ Virginia Præparater til behandling af inflammatoriske reaktioner
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US7255934B2 (en) * 2000-10-23 2007-08-14 National Institute Of Advanced Industrial Science And Technology Composite structure body and method and apparatus for manufacturing thereof
US6620645B2 (en) * 2000-11-16 2003-09-16 G.T. Equipment Technologies, Inc Making and connecting bus bars on solar cells
SG176313A1 (en) * 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
WO2003072597A1 (en) * 2002-02-27 2003-09-04 Ferring Bv Intermediates and methods for making heptapeptide oxytocin analogues
AU2003234716A1 (en) * 2002-04-10 2003-10-27 Joel M. Linden Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US6662088B1 (en) * 2002-06-28 2003-12-09 General Electric Company Methods and systems for inspecting aircraft fuselage frames
US7396825B2 (en) * 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
CA2576826C (en) 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1729355B1 (en) 2005-06-03 2008-11-19 STMicroelectronics S.r.l. Self-aligned process for manufacturing phase change memory cells
US7767686B2 (en) 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
DE102006022450A1 (de) 2006-05-13 2007-11-15 Lanxess Deutschland Gmbh Wässrige Rußdispersionen für Ink-Jet
EP2178369A4 (en) * 2007-07-17 2010-12-15 Combinatorx Inc TREATMENTS OF PROLIFERATIVE DISORDERS OF LYMPHOCYTES B
TW200905703A (en) * 2007-07-27 2009-02-01 Delta Electronics Inc Magnetic device and manufacturing method thereof
PT2306971E (pt) 2008-07-03 2015-06-18 Univ Virginia Patent Found Dosagem unitária de apadenoson

Also Published As

Publication number Publication date
PT2306971E (pt) 2015-06-18
US9415058B2 (en) 2016-08-16
WO2010002473A1 (en) 2010-01-07
MY161655A (en) 2017-04-28
CN102119023B (zh) 2014-04-09
BRPI0913939A2 (pt) 2016-04-26
EP2306971B1 (en) 2015-02-25
US20100003193A1 (en) 2010-01-07
US9662406B2 (en) 2017-05-30
EP2306971A1 (en) 2011-04-13
KR20110028531A (ko) 2011-03-18
EA022348B1 (ru) 2015-12-30
KR20140021726A (ko) 2014-02-20
JP2013237702A (ja) 2013-11-28
DK2306971T3 (en) 2015-05-11
US20140100185A1 (en) 2014-04-10
IL210428A (en) 2016-05-31
HK1156250A1 (en) 2012-06-08
AU2009266317A1 (en) 2010-01-07
CN102119023A (zh) 2011-07-06
US20130017153A1 (en) 2013-01-17
CA2729819A1 (en) 2010-01-07
EA201100132A1 (ru) 2011-08-30
MX2011000193A (es) 2011-03-24
US20170007722A1 (en) 2017-01-12
HRP20150454T1 (hr) 2015-06-19
AU2009266317B2 (en) 2013-12-05
CY1116283T1 (el) 2017-02-08
NZ590489A (en) 2013-01-25
IL210428A0 (en) 2011-03-31
IL245577A0 (en) 2016-06-30
IL245577B (en) 2019-05-30
JP2011526894A (ja) 2011-10-20
US20190022253A1 (en) 2019-01-24
ZA201100163B (en) 2011-09-28
ES2537069T3 (es) 2015-06-02
US20170252463A1 (en) 2017-09-07
PL2306971T3 (pl) 2015-07-31
CA2729819C (en) 2014-08-26
SI2306971T1 (sl) 2015-07-31

Similar Documents

Publication Publication Date Title
SMT201600008B (it) Composti di piridazinone
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI1011587A2 (pt) compostos e composições terapèuticas
BRPI0920521A2 (pt) combinação farmacêutica
DK3097925T3 (da) Farmaceutisk sammensætning
SMT201400069B (it) Formulazione farmaceutica
BRPI1004940A2 (pt) composição farmacêutica
BRPI1015939A2 (pt) composição farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
BRPI0921654A2 (pt) formulação farmacêutica
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0921313A2 (pt) composição farmaucêutica
BR112012003149A2 (pt) composição farmacêutica
BRPI0912171A2 (pt) composição farmacêutica
FR2928356B1 (fr) Distributeur de comprimes
DK2173197T3 (da) Fremgangsmåde
SMT201500123B (it) Dosaggio unitario di apadenoson
BRPI0909764A2 (pt) compostos terapêuticos
BRPI0921301A2 (pt) composição farmacêutica
BRPI0906879A2 (pt) Compostos terapêuticos
FR2937843B1 (fr) Paravent medical
BRPI1008983A2 (pt) formulação farmacêutica
DK2257548T3 (da) Terapeutiske forbindelser
TH115366B (th) รูปแบบขนาดยาของแข็ง